Pharming Launches Joenja in Japan for Rare Disease APDS
Event summary
- Pharming launched Joenja (leniolisib) in Japan for APDS patients aged 4+ following NHI drug price listing.
- Japan is the first market where Joenja is commercially available for children aged 4 to 11.
- OrphanPacific serves as Marketing Authorization Holder and handles supply/distribution in Japan.
- Joenja received MHLW approval in March 2026 as the first treatment specifically for APDS.
The big picture
Pharming’s launch of Joenja in Japan marks a strategic milestone in addressing the unmet needs of APDS patients, particularly children. This expansion into the Japanese market underscores Pharming’s commitment to rare disease treatments and positions it as a key player in the global pediatric biopharmaceutical sector. The partnership with OrphanPacific further strengthens its commercial footprint in Asia.
What we're watching
- Market Expansion
- How Pharming will leverage this launch to expand Joenja’s global reach, particularly in pediatric markets.
- Regulatory Momentum
- Whether the MHLW approval accelerates regulatory reviews for leniolisib in other countries.
- Commercial Execution
- The pace at which OrphanPacific can scale distribution and patient access in Japan.
Related topics